SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015.
SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015.
复制标题
DOI：
10.1007/s12094-015-1455-z
复制
发表时间：
2015-12
期刊：
影响因子：
--
通讯作者：
Massuti B
中科院分区：
文献类型：
--
作者：
García-Campelo R;Bernabé R;Cobo M;Corral J;Coves J;Dómine M;Nadal E;Rodriguez-Abreu D;Viñolas N;Massuti B
据 Torre 等人报道，肺癌是全世界最常见的癌症，也是癌症相关死亡的主要原因 (CA Cancer J Clin 65:87–108, ]。非小细胞肺癌 (NSCLC) 占所有肺癌的 85%。在过去几年中，分期、诊断程序、治疗选择以及分子知识方面取得了多项进展，尽管大多数患者的总体前景并没有发生太大变化。根据 Howlader 等人的报告（SEER 癌症统计评论），过去十年中 5 年生存率略有增加，从 15.7% 增加到 17.4%。
Lung cancer is the most common cancer worldwide as well as the leading cause of cancer related deaths as reported by Torre et al (CA Cancer J Clin 65:87–108, ]. Non-small cell lung cancer (NSCLC) accounts for up to 85 % of all lung cancers. Multiple advances in the staging, diagnostic procedures, therapeutic options, as well as molecular knowledge have been achieved during the past years, although the overall outlook has not greatly changed for the majority of patients with the overall 5-year survival having marginally increased over the last decade from 15.7 to 17.4 % as reported by Howlader et al. (SEER Cancer Statistics Review).